At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
CC100 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Protocol CC100A CC100: Safety and Tolerability of Single Doses
In Brief
A Phase 1 clinical trial evaluating CC100 and Placebo for Healthy. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The purpose of this study is to see if CC100, given by mouth, is safe and is tolerated in increasing doses. How long the drug remains in the body will also be calculated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedJan 2014
Primary CompletionJul 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedJan 30, 2014
Enrollment StartNov 1, 2013
Primary CompletionJul 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.4 years ago
Interventions
CC100drug
CC100 reconstituted in diluent
Placebodrug
Diluent. Amount to match CC100 dose.